These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38761253)

  • 1. From metabolomics to proteomics: understanding the role of dopa decarboxylase in Parkinson's disease. Scientific commentary on: "Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease".
    Shebl N; Salama M
    Acta Neuropathol; 2024 May; 147(1):88. PubMed ID: 38761253
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease.
    Rutledge J; Lehallier B; Zarifkar P; Losada PM; Shahid-Besanti M; Western D; Gorijala P; Ryman S; Yutsis M; Deutsch GK; Mormino E; Trelle A; Wagner AD; Kerchner GA; Tian L; Cruchaga C; Henderson VW; Montine TJ; Borghammer P; Wyss-Coray T; Poston KL
    Acta Neuropathol; 2024 Mar; 147(1):52. PubMed ID: 38467937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease.
    Appleton E; Khosousi S; Ta M; Nalls M; Singleton AB; Sturchio A; Markaki I; Paslawski W; Iwaki H; Svenningsson P
    Transl Neurodegener; 2024 Jun; 13(1):31. PubMed ID: 38863007
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
    Paslawski W; Khosousi S; Hertz E; Markaki I; Boxer A; Svenningsson P
    Transl Neurodegener; 2023 Sep; 12(1):42. PubMed ID: 37667404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF and blood biomarkers for Parkinson's disease.
    Parnetti L; Gaetani L; Eusebi P; Paciotti S; Hansson O; El-Agnaf O; Mollenhauer B; Blennow K; Calabresi P
    Lancet Neurol; 2019 Jun; 18(6):573-586. PubMed ID: 30981640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.
    van Dijk KD; Teunissen CE; Drukarch B; Jimenez CR; Groenewegen HJ; Berendse HW; van de Berg WD
    Neurobiol Dis; 2010 Sep; 39(3):229-41. PubMed ID: 20451609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.
    Trupp M; Jonsson P; Öhrfelt A; Zetterberg H; Obudulu O; Malm L; Wuolikainen A; Linder J; Moritz T; Blennow K; Antti H; Forsgren L
    J Parkinsons Dis; 2014; 4(3):549-560. PubMed ID: 24927756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Trezzi JP; Galozzi S; Jaeger C; Barkovits K; Brockmann K; Maetzler W; Berg D; Marcus K; Betsou F; Hiller K; Mollenhauer B
    Mov Disord; 2017 Oct; 32(10):1401-1408. PubMed ID: 28843022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder.
    Dong MX; Hu L; Wei YD; Chen GH
    Neurosci Lett; 2021 Feb; 745():135626. PubMed ID: 33440238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for Parkinson's Disease: Recent Advancement.
    Lotankar S; Prabhavalkar KS; Bhatt LK
    Neurosci Bull; 2017 Oct; 33(5):585-597. PubMed ID: 28936761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated metabolomics and proteomics analysis of plasma lipid metabolism in Parkinson's disease.
    Gątarek P; Kałużna-Czaplińska J
    Expert Rev Proteomics; 2024; 21(1-3):13-25. PubMed ID: 38346207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.
    Kwon DH; Hwang JS; Kim SG; Jang YE; Shin TH; Lee G
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-based biomarkers for Parkinson's disease.
    Chahine LM; Stern MB; Chen-Plotkin A
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S99-103. PubMed ID: 24262199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.
    Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG
    J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
    Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
    Parkinsonism Relat Disord; 2018 May; 50():108-112. PubMed ID: 29475591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biofluids profile of α-Klotho in patients with Parkinson's disease.
    Sancesario GM; Di Lazzaro G; Grillo P; Biticchi B; Giannella E; Alwardat M; Pieri M; Bernardini S; Mercuri NB; Pisani A; Schirinzi T
    Parkinsonism Relat Disord; 2021 Sep; 90():62-64. PubMed ID: 34392132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid protein biomarkers in Parkinson's disease.
    Faizan M; Sachan N; Verma O; Sarkar A; Rawat N; Pratap Singh M
    Clin Chim Acta; 2024 Mar; 556():117848. PubMed ID: 38417781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.